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Heparanase activity is dysregulated in children with steroid-
sensitive nephrotic syndrome.
Background. Immune cells express heparanase, an endogly-
cosidase, able to degrade heparan sulfate glycosaminoglycan
(HSGAG) in the glomerular capillary wall (GCW) and poten-
tially induce proteinuria. The aim of this study was to determine
whether dysregulated heparanase expression is associated with
the heavy proteinuria of childhood steroid-sensitive nephrotic
syndrome (SSNS).
Methods. Plasma and urinary heparanase activity and pe-
ripheral blood mononuclear cell (PBMC) mRNA heparanase
levels [real-time polymerase chain reaction (PCR)] were mea-
sured in children with SSNS in relapse and remission. Plasma
and urinary heparanase activity was determined in adult pa-
tients with nephrotic syndrome and in age- and gender-matched
controls.
Results. Plasma heparanase activity was reduced in SSNS with
relapse (811.2 units) compared to remission (1147.96 units) (P =
0.003) and control subjects (1390.51 units) (P < 0.001). In adult
nephrotic syndrome, plasma heparanase activity was signifi-
cantly lower in patients compared to controls. However, there
was no difference between remission and relapse states. In chil-
dren, urinary heparanase activity/urinary creatinine ratio was
highest in SSNS relapse (14.26 units/mg) compared with remis-
sion (7.43 units/mg) (P = 0.016) and controls (2.29) (P < 0.001).
However, PBMC heparanase mRNA expression was not differ-
ent between these three groups. In adult nephrotic syndrome,
urinary heparanase activity/urinary creatinine levels were lower
in both remission and relapse compared to controls and there
was no difference between remission and relapse states.
Conclusion. In childhood SSNS, there is a qualitative and
quantitative difference in urinary heparanase activity expres-
sion that is not paralleled in adult nephrotic syndrom. These
data suggest that dysregulated heparanase expression may play
a significant role in the pathogenesis of SSNS, possibly through
an abnormality in post-translational control of latent hep-
aranase activation.
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Childhood steroid-sensitive nephrotic syndrome
(SSNS), the clinical correlate of minimal change dis-
ease, is characterized by the abrupt onset of selective
proteinuria which, if untreated, rapidly results in the
development of generalized edema [1]. Following
successful treatment of the presenting episode with
corticosteroids, the large majority of children follow a
relapsing-remitting course necessitating further courses
of corticosteroids and many require other immuno-
suppressive agents. Considerable evidence supports
a central role for the immune system in the disease
pathogenesis [1] though histologic examination of renal
biopsy tissue does not reveal evidence of glomerular
inflammation involving either antibody and complement
deposition or interstitial cell infiltration. Despite almost
three decades of scientific investigation, particularly
into this link with the immune system [2], the basic
mechanisms underlying the disorder remain undefined.
The glomerular capillary wall (GCW) is an integrated
structure comprising fenestrated endothelium, glomeru-
lar basement membrane (GBM), and podocytes, which
forms an effective filtration barrier to restrict plasma pro-
teins (on the basis of size and charge) from passing out
of the capillary lumen into Bowman’s space. The GBM
and podocyte contribute significantly to the control of
GCW permeability [3]. Podocyte foot process interac-
tion with the GBM [4] and the unique slit pore junctions
between adjacent foot processes [5] are critical for bar-
rier integrity; disruption of podocyte interaction with the
GBM using antibodies to b 1 integrins [6], or modulation
of the specialized slit pores using antibody to nephrin,
induces massive proteinuria in rats [5].
The negative charge barrier in the GCW is a prop-
erty of constitutive heparan sulfate glycosaminoglycan
(HSGAG) side chains [7], which are located around en-
dothelial fenestrae [8] within the lamina rarae of the
GBM [9] and in podocyte plasma membranes [10]. HS-
GAG is present on two proteoglycans in the GBM,
agrin [11] and perlecan [12, 13] in a molar ratio of 6:1,
respectively.
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Heparanase (HSPE), also known as HSE1 and HPA-1,
is an endoglycosidase which depolymerises HSGAG by
limited cleavage of specific internal glycosidic bonds [14].
In normal physiology, the highest levels of heparanase
mRNA are found in placenta, peripheral blood leuko-
cytes, and other immunologic tissues [15, 16]. Physiologic
functions of heparanase are thought to include roles in
structural disassembly of HSGAG and regulation of ac-
tivity of heparan sulfate-binding growth factors [e.g., vas-
cular endothelial growth factor (VEGF)] in basement
membranes and extracellular matrix (ECM)] [17]. These
functions occur in normal tissue remodeling and cellular
invasion (e.g., placental implantation [18] and leukocyte
migration [19]). Heparanase activity is significantly in-
creased in experimental models of autoimmune disease
[20] and tumor invasion and metastasis [21].
Critical experiments demonstrate that destruction or
neutralization of HSGAG increases permeability to pro-
tein in the GCW. Degradation of HSGAG in rat GBM
by perfusion with exogenous flavobacterial heparitinase
(a heparan sulfate-degrading enzyme cleaving HSGAG
at alternative internal sites using a different mechanism
from heparanase) results in increased permeability of
the GBM for anionic ferritin detectable by electron mi-
croscopy [22]. Treatment of glomeruli with bacterial hep-
aritinase effectively doubles the permeability of the filter
to albumin and demonstrates that podocytes contribute
to the charge barrier [23]. Hydroxyl radical depolymer-
ization of HSGAG in a model of nephrotic syndrome [24]
and reduction in HSGAG charge by neutralization with
anti-HSGAG antibodies also induces albuminuria [25].
In experimental models of puromycin aminonucleo-
side (PAN) nephrosis [26] and passive Heymann nephri-
tis [27] in rats, a significant increase in staining for
heparanase is reported in podocytes coincident with the
onset of proteinuria. A recent clinical study of diabetic
nephropathy [28] confirms the findings of our pilot stud-
ies [abstract; Behzad F, et al, J Am Soc Nephrol 12:p831A
2001] that heparanase is present in the urine of approxi-
mately 25% of patients with microalbuminuria and there-
fore may be implicated in the proteinuric mechanism of
diabetic nephropathy.
Our hypothesis is that the underlying immune diathesis
in pediatric SSNS is manifest through dysregulated ex-
pression of heparanase which degrades GBM HSGAG
allowing increased permeability to albumin. Consequent
on an appropriate immune trigger, patients with SSNS ex-
hibit increased urinary heparanase activity at the onset of
proteinuria compared to the period of remission.
The aims of this study were (1) to determine whether
increased urinary heparanase expression is associated
with the heavy proteinuria of childhood SSNS, (2) to
determine whether peripheral blood mononuclear cell
(PBMC) heparanase mRNA or plasma heparanase is
modulated in SSNS patients, and (3) to determine
whether such changes in heparanase expression are spe-
cific to SSNS or common to nephrotic syndrome in
general.
METHODS
All studies on human subjects were performed with
the full informed consent of the subject or their legal
guardian. The pediatric study had the approval of the
Salford and Trafford Local Research Ethics Committee
and the adult study was approved by the Central
Manchester Local Research Ethics Committee.
Studies on children with SSNS and age/gender-matched
controls
Blood and urine samples were collected from a total of
32 children (16 male) with clinically defined SSNS on 42
occasions; 28 times during disease remission and 14 times
while proteinuric (11 during the early stages of disease
relapse within 3 days of the first appearance of protein-
uria and three at the first presentation of nephrotic syn-
drome, which was subsequently confirmed to be steroid
sensitive). Because of the difficulties of sample collection
from small children, complete plasma, urine, and mRNA
sample collection was not possible on each and every
occasion. This precluded an adequately-powered paired
sample analysis.
Confirmation of proteinuric/remission status was per-
formed by scrutiny of home urine test records, phys-
ical examination, and laboratory measurement of the
urine protein/creatinine ratio. None of the proteinuric
patients had received corticosteroid treatment within
14 days prior to sampling, nor received maintenance
immunomodulatory medication (levamisole, cyclophos-
phamide, cyclosporine) within the previous 6 months.
None of the patients in remission had received corticos-
teroids within the preceding 6 weeks, or maintenance
immunomodulatory medication within the previous
6 months.
Pediatric control samples were collected from a total
of 24 age/gender-matched children (15 male) admitted
to hospital for minor surgical procedures. All were in
good general health and none were on regular medica-
tion at the time of study. Samples were collected within
2 minutes of induction of anesthesia prior to the com-
mencement of surgery. A separate venepuncture site was
chosen rather than using the intravenous cannula to ob-
tain samples to avoid any contamination by intravenous
anesthetic agents. Urine specimens were collected prior
to surgery being performed. Urinary creatinine concen-
tration was measured by a standard kinetic Jaffe´ method
using a Hitachi 911 analyser. All samples were stored at
−80◦C prior to analysis.
Plasma for measurement of heparanase activity was
obtained from blood samples by centrifugation at 850g
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for 10 minutes at room temperature. PBMC were iso-
lated from the remaining blood components by density
gradient centrifugation through lymphocyte separation
medium (Gibco, Paisley, UK) and submitted for RNA
extraction, cDNA preparation and quantification of hep-
aranase mRNA expression by real-time polymerase
chain reaction (PCR).
Studies on adults with nephrotic syndrome and normal
adult controls
Plasma and urine samples were taken from the follow-
ing adult groups for measurement of heparanase activity;
they were processed and stored in a similar way to the
pediatric samples.
Adult nephrotic syndrome patients with current pro-
teinuria. Eight adults were studied (five male, mean age
55.1 years) who presented with nephrotic syndrome
(proteinuria > 3.5 g/24 hours) due to biopsy-proven
pathologies, including membranous nephropathy (N =
5), amyloid (N = 1), Alport syndrome (N = 1), and prolif-
erative glomerulonephritis (N = 1). Patients were studied
while proteinuric (>1 g urinary protein/24 hours, mean
5.24 g/24 hours) in the absence of immunosuppressive
therapy.
Adult nephrotic syndrome patients currently in remis-
sion of proteinuria. Ten patients were studied (five male,
mean age 62.3 years) who had previously presented
with nephrotic syndrome due to biopsy-proven patholo-
gies, including membranous nephropathy (N = 6), lupus
nephritis (N = 2), focal segmental glomerulonephritis
(N = 1), and mesangiocapillary glomerulonephritis (N =
1). Patients were studied in remission of proteinuria (<1 g
urinary protein/24 hours, mean 0.22 g/24 hours) in the ab-
sence of immunosuppressive therapy.
Adult nephrotic syndrome patients with minimal change
disease in remission of proteinuria. Four patients were
studied (two male, mean age 69 years) who had previ-
ously presented with nephrotic syndrome and had no
biopsy changes on light microscopy. Patients were stud-
ied in remission of proteinuria (<1 g/24 hours, mean
0.15 g/24 hours) in the absence of immunosuppressive
therapy.
Adult healthy controls. Ten healthy adults (five male,
mean age 37 years) served as normal adult controls.
Heparanase activity assay
Plasma and urine heparanase activity were measured
using a recently reported assay [29]. The assay employs
biotinylated GBM HSGAG as a substrate, immobilized
in reaction wells of 96-well microtiter plates. In brief,
test samples, heparanase standards and controls were
incubated with the substrate employing standard con-
ditions of time, temperature, and assay buffer. After
washing, the remaining plate-bound substrate was de-
tected using streptavidin-peroxidase conjugate and color
was developed using a chromogenic peroxidase substrate.
Reduction in absorbance at 450 nm was plotted against
heparanase activity. The heparanase activity of test
samples was determined by comparison to the standard
curve generated by dilutions of a standard heparanase
preparation. The heparanase standard was prepared from
human platelets as previously described [29] and was
calibrated in heparanase activity units with reference to
an independent heparanase assay (Takara Biomedical,
Shiga, Japan). One heparanase activity unit was defined
as the activity which degraded 63 pg of biotinylated
HSGAG in one minute at pH 5.8 and 37◦C.
RNA extraction and cDNA synthesis
RNA was extracted from PBMC using the Qiagen
RNAeasy isolation system according to the manufac-
turer’s instructions (Crawley, UK). RNA was reverse
transcribed to form cDNA using Qiagen Omniscript re-
verse transcriptase. Reverse transcription (RT) was car-
ried out in a 20 lL reaction volume containing 1 lg of
RNA, 1 × RT buffer, 0.5 mmol/L of each deoxynucleo-
side triphosphate (dNTP), 1 lmol/L oligo dT12−18 primer
(Invitrogen Ltd., Paisley, UK), 10 units RNAse inhibitor
(Invitrogen) and 4 units of reverse transcriptase, for
60 minutes at 37◦C.
TaqMan quantitative real-time PCR analysis
Primers were designed using Primer Express software
(PE-Applied Biosystems, Warrington, UK). Expression
levels of human heparanase were determined using the
following primer pair and probe sequences: forward
5′-cacggacccgcggtt-3′; reverse 5′-ggtacgcaggagacaagcct-
3′; probe 5′-FAM-ccaaagcttcgtaccttggcca-TAMRA-3′.
b-actin housekeeping gene expression was deter-
mined using predeveloped assay reagents (PE-Applied
Biosystems).
Real-time PCR reactions were performed in dupli-
cate for each cDNA and control sample. Heparanase-
specific reactions were performed in 50 lL reaction
volumes containing 100 ng cDNA, 1× TaqMan univer-
sal master mix, 0.9 lmol/L forward and reverse primers,
0.25 lmol/L probe. b-actin specific reactions were car-
ried out using predeveloped assay reagents according the
manufacturer’s instructions. This comprised a 50 lL re-
action volume containing 1 × TaqMan universal master
mix, primers, and probe.
The ABI Prism 7700 sequence detection system (PE-
Applied Biosystems) was used for detecting real-time
quantitative PCR products, with thermal cycling condi-
tions of 50◦C for 2 minutes, 95◦C for 10 minutes, followed
by 40 cycles of 95◦C for 15 seconds, and 60◦C for 1 minute.
Specificity of the products was demonstrated for the hep-
aranase primer set by analysis of products using gel elec-
trophoresis.
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Results of the real-time PCR data were represented
as Ct values, where Ct was defined as the threshold cy-
cle of PCR at which amplified product was first detected.
Ct was the difference in Ct values between heparanase
and b-actin housekeeping control. Normal kidney cDNA
acted as a calibrator to generate a Ct value (Ct test
sample-Ct kidney calibrator sample). The N-fold dif-
ferential expression in heparanase expression when com-
pared to calibrator was expressed as 2Ct.
Evaluation of the linearity of the real-time RT-PCR assay
In order to validate the use of the Ct method as
a measure of heparanase expression levels, the linearity
of the PCR had to be evaluated. To examine linearity, a
serial dilution of RNA (range) was reverse transcribed
to form a cDNA template for subsequent real-time PCR.
The correlation between RNA concentration and the Ct
value of real-time PCR was determined. The linearity
of RNA concentration (log value) vs. Ct values of each
serial dilution was calculated by linear regression analysis
(r = 0.07, data not shown).
Statistical analysis
Statistical analysis was performed using Graphpad
Prism 4.0. Student t test and Pearson correlation test
were used for quantitative data showing a normal dis-
tribution. Nonparametric data sets were analyzed using
the Kruskal-Wallis test, Mann-Whitney U and Spearmans
rho test. Chi-squared test was used for nominal data. Sig-
nificance was attributed to results where P < 0.05.
RESULTS
Comparison of adult and pediatric control samples
No effect of gender on plasma heparanase activity,
PBMC heparanase mRNA expression or urinary/urinary
creatinine ratio was detected in the combined pediatric
and adult control group. However, there was an age-
related difference in plasma heparanase activity. Healthy
children had significantly higher levels of plasma hep-
aranase activity than normal adults (P < 0.001) which
on further analysis revealed a significant inverse correla-
tion between age and plasma heparanase activity (Fig. 1)
(Spearman correlation coefficient r = −0.706, P <
0.0001). The levels of plasma heparanase activity in nor-
mal children were unrelated to either peripheral blood
lymphocyte number (Spearman r = −0.235, P = 0.318)
or platelet count (Spearman r = 0.0135, P = 0.955) (data
not shown).
Plasma heparanase in pediatric SSNS and adult nephrotic
syndrome in remission and relapse compared to controls
Pediatric groups. There was no difference between the
relapse, remission, and control pediatric groups in terms
of age (P = 0.965), or gender (P = 0.495). A significant
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Fig. 1. Correlation between age and plasma heparanase activity (HA),
(N = 20 healthy children and 10 normal adults). A significant inverse
correlation was detected (r = −0.706, P < 0.0001, Spearman rho test,
two-tailed).
difference in plasma heparanase activity was observed
between the study groups (Fig. 2A) (P < 0.001). Plasma
heparanase activity was lowest in the proteinuric phase of
disease [median values (IQR) 811.2 units (478.7–1091.8)]
and was significantly lower than in remission [1147.9
units (1058.5–1214.6), P = 0.003] or in control subjects
[1390.5 units (1071.4–1627.7), P < 0.001). Subjects in the
remission group had intermediate plasma heparanase ac-
tivity levels, which also differed significantly from control
values (P = 0.012).
Adult groups. Plasma heparanase activity was sig-
nificantly lower in the nephrotic syndrome remission
group 520.3 units (683.9–806.7, P = 0.001) and nephrotic
syndrome relapse group 581.2 units (394.2–667.6, P =
0.043) compared to the control group 723.1 (684.0–
806.7). However, there was no difference in plasma hep-
aranase activity between the nephrotic syndrome remis-
sion and nephrotic syndrome relapse groups or between
the control and minimal change disease remission groups
(Fig. 2B).
Urinary heparanase in pediatric SSNS and adult
nephrotic syndrome in remission and relapse compared
to controls
Pediatric groups. A significant difference in urinary
heparanase activity/urinary creatinine ratio was also ob-
served between the study groups (Kruskal-Wallis, P <
0.001). Urinary heparanase activity/urinary creatinine
was highest in the proteinuric phase of disease [14.26
units/mg (8.37–17.60)] and was significantly higher than
in remission [7.43 units/mg (5.06–11.48), P = 0.016] or in
control subjects [2.29 (1.67–3.32), P < 0.001] (Fig. 3A).
Adult groups. Urinary heparanase activity/urinary
creatinine was significantly lower in nephrotic syndrome
remission 0.38 (0.25–0.62, P = 0.0001), in nephrotic
syndrome relapse 1.10 (0.39–1.63, P = 0.0003), and
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Fig. 2. Plasma heparanase activity (HA).
(A) The pediatric study groups comprised
age/gender-matched control subjects (N =
20), steroid-sensitive nephrotic syndrome
(SSNS) disease remission group (N = 27), and
SSNS relapse group (N = 12). (B) Adult study
groups comprised healthy controls (N = 10),
disease remission group, nephrotic syndrome
(NS) remission (N = 10), nephrotic syndrome
relapse group (N = 8), and minimal change
disease (MCD) remission (N = 4). Whisker
bars represent interquartile range (IQR) for
each group.
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Fig. 3. Urine heparanase activity/creatinine
ratio (HA/Cr). (A) The pediatric study groups
comprised age/gender-matched control sub-
jects (N = 20), steroid-sensitive nephrotic syn-
drome (SSNS) disease remission group (N
= 27), and SSNS relapse group, (N = 12).
(B) Adult study groups comprised healthy
controls (N = 9), nephrotic syndrome (NS)
disease remission group (N = 10), nephrotic
syndrome relapse group (N = 8), and mini-
mal change disease (MCD) remission group.
Whisker bars represent interquartile range
(IQR) for each group
in minimal change disease remission 0.22 (range 0.16–
0.39) compared to the controls 3.75 units/mg (2.55–6.22)
(Fig. 3B). There was no significant difference between the
nephrotic syndrome remission and nephrotic syndrome
relapse groups.
Plasma heparanase activity did not correlate with
urinary heparanase activity/urinary creatinine ratio in
nephrotic adult and pediatric patients (Fig. 4A) or in nor-
mal adults and children (Fig. 4B).
Real-time PCR for heparanase mRNA
PBMC heparanase mRNA expression measured by
real-time PCR was not different between the three groups
[2.49 units (1.41–3.45) vs. 2.04 units (1.60–2.36) vs. 2.40
units (1.81–3.93), respectively, Kruskall-Wallis P = 0.156]
(Fig. 5).
DISCUSSION
The clinical presentation of SSNS has a number of in-
triguing components that require explanation and inte-
gration into any working hypothesis of the mechanism of
disease. The early age of onset (median 2 years) with a
relapsing and remitting pattern of highly selective pro-
teinuria coupled with the tendency for children to out-
grow their disease is suggestive of an inherent defect in
the ability to maintain control of capillary permeability
which resolves over time. Renal biopsy evidence shows
apparently normal structural definition of the GCW, ab-
sence of inflammatory cells, or reactants, with characteris-
tic podocyte foot process effacement common to protein-
uric states. Traditionally, the focus for an inherent defect
in SSNS has been the immune system, which normally
matures significantly in the first decade of life. The con-
cept of an immune-derived factor that modulates the per-
meability of the GCW has been the predominant theme
of investigation for nearly 30 years and, as yet, no re-
producible factor has been characterized [2]. A common
problem associated with many proposed permeability
factors has been defining the mechanism by which the
putative factor induces selective albuminuria in the face
of a noninflammatory pathology.
Our group has previously proposed that heparanase is
an interesting candidate mediator of the pathophysiology
of SSNS [2, 30, 31] as it possesses the property of degrad-
ing HSGAG within the GCW, altering permeability to
albumin. Following the identification of the heparanase
gene in 1999 [15, 16, 32, 33], knowledge of heparanase
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Fig. 4. Correlation of paired plasma heparanase activity (HA) and
urine heparanase activity/creatinine ratio (HA/Cr) levels. (A) Protein-
uric adults and children. (B) Normal adults and children analyzed by
Spearman test. There was no significant correlation in either case.
biology has strengthened the case and enabled develop-
ment of reagents and methods to quantitate heparanase
in the clinical situation.
Plasma heparanase is likely to originate from several
sources in the vasculature. All classes of leukocyte and en-
dothelial cells [15, 16] are known to express heparanase
which could be secreted or shed from plasma membranes
into the circulation. At physiologic pH, the enzyme is
inactive yet retains the ability to bind HSGAG and act
as a cell adhesion receptor. The inverse relationship be-
tween plasma heparanase activity and age, with young
children demonstrating plasma heparanase activity al-
most twice that of adults, highlights the need for age-
matching of patients and controls. The explanation for
higher plasma heparanase activity in normal children is
uncertain. Children have increased numbers of lympho-
cytes in the peripheral blood compartment compared to
adults but there is no association between lymphocyte
count and heparanase activity.
In children with SSNS in remission, plasma heparanase
activity is lower and urinary heparanase activity higher
compared to age- and gender-matched healthy con-
trols, reflecting an inherent quantitative difference in
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Fig. 5. TaqMan Qn for PBMC heparanase mRNA in pediatric study
groups. Whisker bars represent interquartile range (IQR) for each
group. Analysis of variance using Kruskal-Wallis test shows no differ-
ence between the groups (P = 0.156).
heparanase expression in SSNS. This altered state of
heparanase activity in SSNS is further exaggerated on in-
duction of proteinuria with a 29% reduction of plasma
heparanase activity and 92% increase in urine hep-
aranase activity compared to remission.
This pattern of heparanase expression appears to be
specific for SSNS in children and not common to the
nephrotic state in general as exhibited by the syndrome
associated with disease in adults. In this latter situation,
the plasma heparanase in the proteinuric group is not dif-
ferent from the remission group. Furthermore, urinary
expression is lower not higher in patients compared to
controls and there is no significant difference between
remission and relapse states.
Significant mRNA expression was identified by real-
time PCR in circulating PBMCs confirming results from
Northern blotting [16]. However, no differences were
identified in mRNA levels in PBMCs in remission and
relapse compared to age-matched controls. This suggests
that the immune triggers for relapse do not lead to in-
creased heparanase transcriptional activity. If PBMCs are
the source of heparanase-mediating damage to the GBM
filter, the regulation of heparanase activity in SSNS is,
therefore, likely to be post-translational. Currently, two
mechanisms of controlling heparanase enzymic activity
exist; first through degree of activation of latent hep-
aranase and second through control of the local redox
environment which we have shown governs level of hep-
aranase activity [34].
What might be the explanation for low plasma levels
of heparanase activity in SSNS in remission with lower
levels in relapse? Several possibilities require investi-
gation. First, reviewing the molecular characteristics of
heparanase that might control its filtration through the
GCW, the latent enzyme (65 kD) and the active enzyme
128 Holt et al: Heparanase in SSNS
(58 kD) which at physiologic pH are likely to be weakly
cationic (based on ion exchange column binding), might
be expected, simply on size and charge properties, to pass
freely through the GCW. Currently there are no data from
experimental models to illustrate this situation. However,
we found no relationship between plasma and urinary
levels of heparanase in nephrotic patients (Fig. 4A) or in
the control groups (Fig. 4B) indicating that urinary hep-
aranase is not simply derived from the circulating plasma
pool. The magnitude of the change in urinary heparanase
activity between remission and relapse (increase of 92%)
is many fold less than the equivalent change in total urine
protein, suggesting that the change is not merely reflect-
ing protein loss.
It seems likely that heparanase shed or secreted into
plasma interacts with circulating cells and endothelial
cells in the vasculature both of which display cell sur-
face HSGAG. Heparanase is known to bind to HSGAG
at physiologic pH without degrading the substrate [35].
This concept that heparanase mediates cell adhesion in-
dependently of its enzyme activity has recently been es-
tablished [36]. This property of heparanase to bind to
HSGAG at physiologic pH without degrading the sub-
strate may explain the reported heparanase deposition in
arterial walls in normal tissues [37]. Second, it has been
demonstrated that extracellular heparanase can bind to
cell surface receptors, is endocytosed and stored in endo-
somal structures in the cell [38]. This process might be part
of a mechanism of controlling plasma heparanase levels
or of delivery of heparanase to cells unable to express
their own endogenous enzyme. Therefore, the explana-
tion of lower plasma heparanase activity in SSNS might
be due to a greater uptake of heparanase by cells in and
lining the vasculature.
An alternative explanation is that there is present in
SSNS plasma an inhibitor of heparanase activity. A can-
didate inhibitor is HSGAG itself which would be re-
leased following heparanase activity, and which like other
oligosaccharide sulfated compounds (heparin) contains
inhibitory sequences [29, 39].
The finding of increased heparanase activity in urine in
remission with further increase in relapse could be indica-
tive of intrarenal production of heparanase. In an exper-
imental model of PAN nephrosis in rats, heparanase was
identified by immunostaining in tubular cells of the dis-
tal convoluted tubules and thick ascending limb of Henle
in normal kidney with minimal expression in glomeruli
[26]. However, at day 5, coincident with the onset of pro-
teinuria in this model, significant increase in staining for
heparanase was reported in podocytes. In a study of hep-
aranase expression in Heymann nephritis [27], adminis-
tration of antiheparanase antibody early in the course of
proteinuria significantly reduced urinary protein excre-
tion, suggesting that heparanase contributes to the pro-
teinuric mechanism of this model.
We have previously reported heparanase in urine from
patients with diabetes [abstract; Behzad F, et al, J Am
Soc Nephrol 12:p831A 2001] and a recent study confirms
heparanase is present in urine in approximately 25% of
patients with microalbuminuria [28]. Immunochemical
staining localized heparanase to glomerular capillaries
and tubular epithelium with lysates of glomerular and
mesangial cells showing significant heparanase activity.
The finding that heparanase can be up-regulated in kid-
ney in disease with increased expression of urinary hep-
aranase requires specific confirmation in SSNS. However,
current clinical practice in pediatric SSNS is not to rou-
tinely undertake biopsy at disease presentation and im-
munostaining of heparanase on kidney tissue in our study
was not possible. However, this is currently under investi-
gation in a separate study of adult cases of SSNS showing
minimal change on renal biopsy.
The recent development of a transgenic mouse line
overexpressing human heparanase has identified a renal
phenotype consistent with minimal change disease with
foot process effacement, no inflammatory infiltrate and a
fivefold increase in urinary protein/creatinine ratio [40].
This is very supportive evidence for the hypothesis that
heparanase is involved in modulating the permeability
of the GBM to albumin through removal of HSGAG.
Exploitation of this model using passive transfer of lym-
phocytes over expressing heparanase into normal animals
should allow precise delineation of the role of lymphocyte
heparanase in this proteinuric mechanism.
Our study clearly identifies a defect in heparanase
regulation present in the remission state, which is ex-
acerbated at the time of relapse. Heparanase has the
properties required to produce the selective proteinuria
associated with SSNS. The primary source of heparanase
may originate from either the immune system or the kid-
ney and it is possible that either or both may contribute
to excess activity sufficient to exceed a threshold to in-
duce proteinuria. Antagonists of heparanase may offer
potential treatment of SSNS and, therefore, avoid the
complications of repeated courses of corticosteroids or
other immunomodulatory agents.
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